Only a Few Minutes to Pull Up Akanda Corp. (NASDAQ: AKAN) Before the Bell

Market Crux Announces Next Profile for Friday! Consider Adding Akanda Corp. (NASDAQ: AKAN) to Your Watchlist Early This Morning! Akanda Corp. (NASDAQ: AKAN) Comes Backed by Several Potential  Catalysts Including: Ultra Low Float: Less Than 800k Shares, Potential For Significant Swings With Demand Changes! Under the Radar: Market Cap Under $3M (As Of 10/10/2024), Could Witness Rapid Valuation Changes Compared To Larger Companies! Robust Market Potential: Global Pharma (CB) Market Expected To Grow a Staggering 4,514%, From $9.33B To Over $430.5B By 2032! Expansion Into Canada: Acquired Canadian Farming Property In British Columbia, Plans For (CB) Facilities. German Market Entry: Evaluating Growth Plans And Acquisitions In Germany's CBPM Market, Projected To Reach Over $5.7B By 2030.  US Federal Policy Changes: Preparing To Capitalize On (CB) Rescheduling To Schedule III In The US, Anticipating Favorable Market And Regulatory Changes! October 11, 2024 Dear Reader, Consider turning your attention to Akanda Corp. (NASDAQ: AKAN) this morning. If you've been following us closely, you likely saw the low float profile we shared Wednesday. It closed at $1.12 they day before and reached a high of $1.20 yesterday, up approximately 20% since Monday’s low of $.998. And let’s not forget last Thursday's low-floater, which capped off an approximate 226% move earlier this week on Monday. Now, it's time to prepare for what's coming next. For those who haven’t met me yet, my name is Gary Silver, Managing Editor of Market Crux Newsletter.  My goal is to introduce you to hidden gems in the market—those companies with growth potential that have yet to catch the attention of Wall Street. And now we are turning our attention to Akanda Corp. (NASDAQ: AKAN). But don’t wait on this one because Akanda Corp. (NASDAQ: AKAN) has less than 800K shares in its float, which means there’s the potential for significant swings if there’s a shift in demand. Akanda Corp. (NASDAQ: AKAN) is also considered a nano-cap. In general, nano-cap companies have market capitalizations of less than $50M. Because nano-cap stocks are significantly smaller than mid cap or large cap companies, they have a higher potential to change valuation quickly. As of yesterday, 10/10/2024, Akanda Corp. (NASDAQ: AKAN) has a market cap of less than $3.5M (approx.). Akanda Corp. (NASDAQ: AKAN) is positioning itself in a market with the potential to grow a staggering 4,514%. The global CB Pharma market is expected to grow a staggering 4,514% from $9.33B to over $430.5B by 2032, indicating a significant increase in demand and market size. Keep reading to see why Akanda Corp. (NASDAQ: AKAN) needs to be at the top of your watchlist right now. Akanda Corp. (NASDAQ: AKAN) is an international medical cann-a-bis (CB) and wellness platform company committed to enhancing lives through improved access to high-quality and affordable CB products.  The company’s extensive portfolio includes CanMart, a UK-based, fully licensed pharmaceutical importer and distributor that supplies pharmacies and clinics throughout the UK. In the UK, all pharmaceutical products containing C-B-D are referred to as CB-based products for medicinal use (CBPM). Akanda Corp. (NASDAQ: AKAN)’s comprehensive seed-to-patient supply chain is bolstered by its partnerships with notable entities such as Cellen Life Sciences' Leva Clinic, one of the first fully digital pain clinics in the UK.  Moreover, Akanda has acquired the rights to develop a Canadian farming property in British Columbia, which includes farming land, related operations, and licenses. The company plans to establish CB facilities at this site, further expanding its capabilities. Recent Developments Akanda Corp. (NASDAQ: AKAN) Secures Hemp Cultivation License in Canada, Expanding Footprint in the CB Market… Akanda Corp. (NASDAQ: AKAN) recently announced the acquisition of a hemp cultivation license in Canada, marking a pivotal step in the company's ongoing expansion strategy.  This license aligns with Akanda Corp. (NASDAQ: AKAN)’s previous development agreement with 1107385 B.C. LTD and furthers its presence in the Canadian CB industry. This recent achievement reinforces Akanda’s strategic commitment to growth and leadership in the global CB market. By securing this license, the company is set to accelerate its operations and solidify its competitive edge in one of the industry's most dynamic markets. In a strategic move, Akanda Corp. (NASDAQ: AKAN) also announced plans to commercialize and capitalize on Germany's recent le-gal-iza-tion of CBPM, which opens a pathway to a $3B market.  Germany, the third European Union country to LGLize CB for personal use after Malta and Luxembourg, enacted this law on April 1, 2024.  This LGLization permits recreational possession, allows individuals to grow up to three plants, and enables joining CB clubs to buy up to 25 grams per day. Akanda Corp. (NASDAQ: AKAN) anticipates significant growth potential in this expanded LGL market.  The company is actively evaluating potential acquisitions and strategic expansion in Germany, focusing on cultivation, production, and retail areas where its management and board have substantial experience.  Akanda Corp. (NASDAQ: AKAN) believes the expansion in both medical and recreational CBPM use will drive increased patient and consumer demand.  The company plans to closely monitor regulatory developments and the licensing process, as well as assess current licensed operating targets for potential acquisition. Akanda's interim CEO and Director, Katie Field, stated,  "We applaud Germany's increased access to valid medicine and products for patients and consumers. This legislation represents a critical step and illustrates a public policy model for other European Union countries. Akanda is evaluating the potential to participate at the leading edge of this market and aspires to provide German consumers with exceptional products." The German CBPM market, valued at approximately $1.17B in 2022, is projected to reach over $5.7B by 2030, exhibiting a CAGR of 22.05% during the forecast period 2023-2030. The LGLization and sale of CB are advancing rapidly not only in the U.S. but globally. Global CB sales are expected to increase from $13.4B to over $148B by 2031. Strategic Moves in the US Following Federal Policy Changes Akanda Corp. (NASDAQ: AKAN) is also positioning itself to be among the international first movers following the anticipated landmark change in US federal policy regarding CBPM.  It has been widely reported that the DEA plans to reclassify CB as a Schedule III substance as of April 30, 2024.  Akanda Corp. (NASDAQ: AKAN) believes this rescheduling could reinvigorate capital markets and potentially lead to changes in NASDAQ and NYSE rules on listing plant-touching U.S. companies. In response to these potential changes, Akanda has strategic plans to become a leader in consolidating US-based operators.  The company is closely monitoring the loosening of federal regulations and plans to explore potential strategies within the US market.  Akanda Corp. (NASDAQ: AKAN)’s board and management have extensive expertise in multiple global markets, including the United States, and are prepared to capitalize on these developments. Key Market Insights Germany: Pioneering Shops for Scientific Purposes Germany is progressing with the second pillar of its CBPM LGLization law by setting up municipal five-year pilot programs for state-controlled CBPM to be sold in licensed shops. The Ministry of Agriculture is drafting regulations focused on the "permission and monitoring of the use of CBPM for scientific purposes." This innovative approach underscores Germany's commitment to creating a structured and regulated market. United Kingdom: Soaring Medical Sales The United Kingdom is experiencing unexpectedly high CBPM sales driven by unusually high per-patient consumption rates. A new report by Prohibition Partners reveals that by the end of 2024, approximately 62,960 patients in the UK will be using CBPM, generating sales of 240M eu-ros ($258.8M). This equates to an average annual consumption of 3,811 eur-os per patient, significantly higher than in Germany, where the average annual consumption per patient is 1,563 eur-os. Akanda Corp. (NASDAQ: AKAN) is strategically positioned to capitalize on significant market potential in both Europe and the United States. With a robust portfolio, strategic partnerships, and a proactive approach to regulatory changes, Akanda is poised to become a leader in the global CBPM industry.  The company's focus on high-quality, affordable products and its commitment to improving access for patients and consumers underline its potential for sustained growth and success in the rapidly evolving CBPM market. Here’s 7 reasons to consider researching Akanda Corp. (NASDAQ: AKAN)... 1. Under the Radar: As a nano-cap company with a market cap of less than $3M (as of yesterday (10/10/2024), Akanda Corp. (NASDAQ: AKAN) has a higher potential for growth compared to larger companies. 2. Ultra Low Float: With less than 800K shares in its float, Akanda Corp. (NASDAQ: AKAN) has the potential for significant movements if demand begins to shift. 3. Robust Market Potential: The global CB Pharma market is expected to grow a staggering 4,514% from $9.33B to over $430.5B by 2032, indicating a significant increase in demand and market size. 4. Strategic Global Partnerships: Akanda Corp. (NASDAQ: AKAN)’s portfolio includes CanMart, a UK-based pharmaceutical importer and distributor, and partnerships with entities like Cellen Life Sciences' Leva Clinic, enhancing its reach and credibility. 5. Expansion into Canada: The acquisition of a Canadian farming property in British Columbia, with plans to develop CB facilities, signifies Akanda Corp. (NASDAQ: AKAN)’s growth and diversification in North America. 6. German Market Entry: With Germany LGLizing CBPM, Akanda Corp. (NASDAQ: AKAN) is evaluating strategic moves and acquisitions in a market projected to reach over $5.7B by 2030, providing a substantial growth avenue. 7. US Federal Policy Changes: With the anticipated reclassification of CB as a Schedule III substance in the US, Akanda Corp. (NASDAQ: AKAN) is preparing to be a first mover in the American market, with potential regulatory changes set to boost the industry. Start your research on Akanda Corp. (NASDAQ: AKAN)... Akanda Corp. (NASDAQ: AKAN) stands out as a nano-cap company flying under the radar, with a market cap of under $3M and an ultra-low float of fewer than 800K shares. This unique profile positions Akanda for significant growth, especially as it taps into the booming global CB Pharma market, projected to surge 4,514% by 2032. Through strategic global partnerships and expansion into key regions like Canada and Germany, Akanda Corp. (NASDAQ: AKAN) is aligning with new markets in both medical and recreational CB sectors.  With anticipated changes in US federal policy, Akanda Corp. (NASDAQ: AKAN) is positioning itself to become a first mover in the American market, potentially unlocking even more value in the near future.  Keep a close eye on Akanda Corp. (NASDAQ: AKAN) this morning. Make no mistake. Akanda Corp. (NASDAQ: AKAN) has a very small float and you need to have it on your radar early this morning. I’ll check back with you shortly. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux (MarketCrux . com) is owned by Headline Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. MarketCrux full disclosure is to be read and fully understood before using MarketCrux website, or joining MarketCrux's email or text list. By viewing MarketCrux website and/or reading MarketCrux email or text newsletter you are agreeing to MarketCrux full disclosure which can be read at marketcrux.com/disclaimer Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired by TD Media LLC for a period beginning on 10/10/2024 and ending on 10/11/2024 to publicly disseminate information about (AKAN:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand USD (“Funds”) to disseminate information about (AKAN:US) via digital communications. To date, including under the previously described agreement, Headline Media LLC has been paid twelve thousand USD (“Funds”) by TD Media LLC. These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and who does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC or their members own shares of (AKAN:US). Please see important disclosure information here: https://marketcrux.com/akan-disclosure-691/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice